Vancomycin-resistant enterococcal bloodstream infection-related mortality: Focus on the lack of appropriate therapy [1]

Clinical Infectious Diseases

Volumn 42, Issue 8, 2006, Pages 1203-1204

  Nannini, Esteban C ^a,b  

^a Sanatorio Parque   (Argentina)

^b FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; APPROPRIATE TREATMENT; BACTEREMIA; BACTERIAL VIRULENCE; BLOODSTREAM INFECTION; CLINICAL TRIAL; DRUG EFFICACY; ENTEROCOCCAL INFECTION; ENTEROCOCCUS; EXPERIMENTAL MODEL; HUMAN; INAPPROPRIATE TREATMENT; LETTER; META ANALYSIS; MORTALITY; NONHUMAN; PRIORITY JOURNAL; THERAPEUTIC ERROR; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANIMALS; BACTEREMIA; DISEASE MODELS, ANIMAL; ENTEROCOCCUS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; VANCOMYCIN RESISTANCE;

EID: 33645764167     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/502653     Document Type: Letter

References (14)

1. DiazGranados CA, Zimmer SM, Klein M, Jernigan JA. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clin Infect Dis 2005; 41:327-33.
2. Linden PK, Pasculle AW, Manez R, et al. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis 1996; 22:663-70.
3. Lodise TP, McKinnon PS, Tam VH, Rybak MJ. Clinical outcomes for patients with bacteremia caused by vancomycin-resistant Enterococcus in a level 1 trauma center. Clin Infect Dis 2002; 34:922-9.
4. Vergis EN, Hayden MK, Chow JW, et al. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia, a prospective multicenter study. Ann Intern Med 2001; 135:484-92.
5. Bhavnani SM, Drake JA, Forrest A, et al. A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. Diagn Microbiol Infect Dis 2000; 36:145-58.
6. DiazGranados CA, Jernigan JA. Impact of vancomycin resistance on mortality among patients with neutropenia and enterococcal bloodstream infection. J Infect Dis 2005; 191: 588-95.
7. Garbutt JM, Ventrapragada M, Littenberg B, Mundy LM. Association between resistance to vancomycin and death in cases of Enterococcus faecium bacteremia. Clin Infect Dis 2000; 30: 466-72.
8. Shay DK, Maloney SA, Montecalvo M, et al. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis 1995; 172:993-1000.
9. Lautenbach E, Bilker WB, Brennan PJ. Enterococcal bacteremia: risk factors for vancomycin resistance and predictors of mortality. Infect Control Hosp Epidemiol 1999; 20: 318-23.
10. Lucas GM, Lechtzin N, Puryear DW, Yau LL, Flexner CW, Moore RD. Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: comparison of clinical features and outcomes. Clin Infect Dis 1998; 26: 1127-33.
11. Nannini EC, Murray BE. Vancomycin-resistant enterococci. In: Fong IW, Drlica K, eds. Reemergence of established pathogens in the 21st century. Plenum: New York: Kluwer Academic, 2003:155-204.
12. Noskin GA, Peterson LR, Warren JR. Enterococcus faecium and Enterococcus faecalis bacteremia: acquisition and outcome. Clin Infect Dis 1995; 20:296-301.
13. Suppola JP, Kuikka A, Vaara M, Valtonen W. Comparison of risk factors and outcome in patients with Enterococcus faecalis vs. Enterococcus faecium bacteraemia. Scand J Infect Dis 1998; 30:153-7.
14. Garsin DA, Sifri CD, Mylonakis E, et al. A simple model host for identifying gram-positive virulence factors. Proc Natl Acad Sci U S A 2001; 98:10892-7.